PRMT5 and neoplasm: GSK3203591 and GSK3368715 have been reported to synergistically inhibit tumor growth in vivo, possibly through a tumor-specific accumulation of 2-methylthioadenosine, an endogenous inhibitor of PRMT5, which correlates with sensitivity to GSK3368715 in cell lines (Fedoriw et al., 2019).